Amvuttra Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Amvuttra market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to factors such as the increasing prevalence of transthyretin amyloidosis (ATTR), a rise in chronic diseases, greater disease awareness, a higher prevalence of hereditary transthyretin-mediated amyloidosis (hATTR), and increased healthcare spending.

Growth during the forecast period is expected to be driven by innovations in RNA interference (RNAi) technology, the expansion of indications, rising disposable incomes, growing awareness and diagnosis of rare diseases, government support, and regulatory incentives. Key trends in the forecast period include the development of long-acting injectable formulations, a shift toward personalized and genetic therapies, increased research and development efforts, integration with other treatments, and advancements in telemedicine.

The increasing prevalence of hereditary transthyretin-mediated amyloidosis (hATTR) is expected to drive the growth of the amvuttra market in the coming years. hATTR is a rare genetic disorder where mutations in the transthyretin protein cause misfolding, leading to amyloid deposits that damage various organs. The rise in hATTR cases is due to several factors, including an aging population, environmental and lifestyle influences, and advancements in genetic screening. Amvuttra works by reducing the production of abnormal transthyretin (TTR), preventing amyloid buildup and slowing disease progression in hATTR patients. The treatment has shown significant benefits in alleviating symptoms and preventing organ damage. For example, a 2022 report from the National Library of Medicine revealed that 2.4% of the general population in the U.S. is affected by peripheral neuropathy, with the prevalence rising to 8% in older adults. As a result, the growing incidence of hATTR is contributing to the expansion of the amvuttra market.

A key trend in the amvuttra market is the advancement of subcutaneous RNAi therapeutics designed to improve treatment convenience and adherence for hATTR amyloidosis. These developments focus on less frequent dosing schedules and extended drug release, addressing the challenges of managing chronic conditions such as polyneuropathy. For example, in June 2022, Alnylam Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) had approved AMVUTTRA for the treatment of polyneuropathy in adults with hATTR amyloidosis. The treatment significantly improves neuropathy symptoms and halts disease progression. In the HELIOS-A Phase 3 study, over 50% of patients saw a reversal or cessation of disease manifestations. AMVUTTRA is also associated with a promising safety profile, with no drug-related discontinuations or deaths, and its dosing regimen may improve patient compliance.

In April 2024, Medison Pharma, an Israeli pharmaceutical company, expanded its partnership with Alnylam Pharmaceuticals to enhance global access to Alnylam's RNAi therapies for patients with rare diseases. This collaboration aims to leverage Medison's commercialization platform across regions such as Latin America (LATAM), the Asia-Pacific (APAC), and other international markets. Alnylam Pharmaceuticals, based in the U.S., manufactures Amvuttra.

The key company operating in the amvuttra market is Alnylam Pharmaceuticals Inc.

North America was the largest region in the amvuttra market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in amvuttra report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the amvuttra market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Amvuttra is a prescription small interfering RNA (siRNA) therapy designed to reduce the production of transthyretin (TTR) protein in the liver. It works by targeting and degrading the messenger RNA (mRNA) responsible for TTR synthesis, which helps prevent the accumulation of amyloid deposits. This treatment aims to alleviate symptoms such as pain, weakness, and reduced mobility, ultimately improving or stabilizing the patient's quality of life.

Amvuttra is primarily indicated for hereditary transthyretin-mediated amyloidosis (hATTR), which includes adult polyneuropathy and cardiomyopathy. hATTR is a rare genetic condition caused by a mutation in the TTR gene, leading to the abnormal buildup of proteins that can damage nerves, the heart, and other organs. The drug is distributed through various channels, including hospital pharmacies, specialty pharmacies, retail pharmacies, and online platforms, and is used by a wide range of patients, including adults and the elderly.

The amvuttra market research report is one of a series of new reports that provides amvuttra market statistics, including the amvuttra industry global market size, regional shares, competitors with the amvuttra market share, detailed amvuttra market segments, market trends, and opportunities, and any further data you may need to thrive in the amvuttra industry. This amvuttra market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The amvuttra market consists of sales of pre-filled syringes and vials for subcutaneous injection. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.